GET DAILY SIGNALSEdwards Lifesciences (EW) Posts Strong Q3 2026 Results on TAVR and TMTT Growth
Key Takeaways
- Edwards Lifesciences reported third-quarter 2026 net sales of $1.72 billion, up about 10% from $1.55 billion a year earlier and ahead of the $1.68 billion consensus estimate.
- Adjusted earnings per share (EPS) rose 19% year over year to $0.80, beating analyst expectations of $0.74 by $0.06.
- Transcatheter Mitral and Tricuspid Therapies (TMTT) sales jumped 44% to $207 million, while Transcatheter Aortic Valve Replacement (TAVR) sales grew 8% to $1.24 billion.
- Management raised its full-year 2026 sales growth outlook to roughly 11.5% and lifted its adjusted EPS guidance to $2.97–$3.05.
- The company issued fourth-quarter 2026 guidance for sales of $1.67–$1.75 billion and adjusted EPS of $0.61–$0.69.
- For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated EW pages on Tickeron.
- To discover AI-driven trading strategies and automated stock-picking ideas, explore Tickeron's Trending AI Robots.
Earnings Context and Why It Matters
Edwards Lifesciences stands out as a key player in structural heart devices, with its TAVR franchise serving as the foundation for treating aortic stenosis without the need for open-heart surgery. This quarter's results carry particular weight because procedure volumes in TAVR and the rapid expansion of the TMTT portfolio represent the main engines behind the company's longer-term revenue path. I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry. Investors tend to focus on margin trends as well, given the ongoing strategic investments in R&D and SG&A spending. The report follows a string of positive clinical and regulatory updates, including recent FDA approvals, so it serves as an important checkpoint on whether that momentum is translating into steady financial progress.
Reported Results
Edwards Lifesciences posted third-quarter 2026 net sales of $1,715.5 million, reflecting roughly 10% growth from $1,553.1 million in the same period last year and exceeding the $1.68 billion consensus figure. GAAP diluted EPS came in at $0.53, compared with $0.50 a year earlier. Adjusted EPS reached $0.80, marking a 19% increase from the prior year's $0.67 and surpassing the $0.74 analyst estimate by $0.06.
Performance across segments highlighted the dual growth drivers. TAVR sales advanced 8.0% to $1.24 billion, or 8.8% on a constant-currency basis, with comparable gains in both the U.S. and international markets. TMTT sales climbed 44.0% to $207 million, or 45.6% in constant currency. Surgical sales rose 2.5% to $264 million. GAAP gross margin improved to 78.5% from 77.8%, and adjusted operating margin widened to 30.3% from 27.5%.
Market Reaction and Investor Sentiment
The quarter produced a clear beat on revenue and earnings, with adjusted EPS clearing consensus by $0.06 and sales exceeding estimates by around $40 million. Stronger TAVR and TMTT results, paired with the raised full-year outlook, point to a generally positive reception from investors. Sentiment had already been supported by favorable trial data and recent FDA approvals in the structural heart area. The central question now centers on whether the updated guidance and ongoing TMTT momentum support the current valuation, especially as analyst price targets have moved higher in recent weeks.
Forward Outlook and Key Factors to Monitor
After the solid third quarter, Edwards raised its full-year 2026 sales growth guidance to about 11.5%, from the previous range of 10% to 11%. TAVR growth guidance was lifted to 9% to 9.5%, and the TMTT sales target was increased to $780 million to $790 million. Full-year adjusted EPS guidance moved to $2.97 to $3.05, from the prior $2.95 to $3.05 range.
Fourth-quarter projections call for total sales between $1.67 billion and $1.75 billion, with adjusted EPS expected in the $0.61 to $0.69 range. I’m watching this closely to see whether TAVR procedure volumes hold their pace and if TMTT’s expansion carries forward into 2027. Important areas to track include adoption rates for newly approved devices, the effects of recent Medicare coverage decisions on TAVR access, and margin trends as R&D and SG&A investments continue through the year. Management plans to provide 2027 and longer-term guidance at its December 2026 investor conference, which could serve as a notable catalyst.
Using Tickeron’s AI Tools for Deeper Analysis
In reviewing the earnings details and segment trends, I turned to Tickeron’s AI Screener to quickly compare Edwards Lifesciences against peers in the medical devices space. The tool’s ability to apply filters for fundamentals, technical patterns, and performance metrics helped surface relevant context without manual effort. It offers a practical way to monitor evolving conditions around names like EW and identify similar opportunities as market dynamics shift.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EW in upward trend: price rose above 50-day moving average on October 21, 2026
EW moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on EW as a result. In 58 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for EW just turned positive on October 14, 2026. Looking at past instances where EW's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
The 10-day moving average for EW crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +6.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where EW advanced for three days, in 172 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
EW broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EW entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 25 (best 1 - 100 worst), indicating outstanding price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.167) is normal, around the industry mean (4.338). P/E Ratio (54.707) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (1.852) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (7.974) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of products to treat late-stage cardiovascular disease
Industry MedicalNursingServices
Advertisement